BioXcel Therapeutics is trading 5.7% up in pre-market at $0.78 after disclosing $1.25 million in additional term loans under its August 24, 2026 credit amendment.
- The financing included a $250,000 upfront fee and reduced the minimum liquidity covenant to $250,000, highlighting significant near-term funding pressure.
- The agreement requires a capital solution or full debt repayment by August 31, 2026.